Champions Oncology, Inc. (NASDAQ:CSBR) was founded in 1985, formerly known as Champions Biotechnology, Inc., changed to its current name in April 2011, headquartered in Hackensack, New Jersey, USA, with 92 full-time employees, is a company A company that develops and sells technical solutions and products in the United States to personalize the development and use of oncology drugs.
Champions Oncology, Inc. (CSBR):
The Tumorgraft Technology Platform of Champion Tumor Company is a method for personalized cancer care based on implanting human tumors in immunodeficient mice.
Champions Oncology provides personalized oncology solutions (POS) through its Tumorgraft Technology Platform (Tumorgraft Technology Platform), and helps doctors develop personalities for cancer patients through tumor-specific data obtained by drug groups and related personalized oncology services Chemical treatment plan.
Champion Oncology also provides POS products, including personalized tumor boards, which are designed to provide oncologists with expertise in specific tumor types; and provide methods for gene sequencing to analyze the genetic makeup of patient tumors to identify potentially useful drugs.
In addition, Champions Oncology also provides translational oncology solutions, including preclinical tumor transplantation platforms for pharmaceutical and biotech companies.
Champions Oncology, Inc. sells its products to patients and doctors via the Internet and sales staff.